<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBo 去TaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230823180653&amp;fc=20230708114047&amp;v=2.17.9。邮政6 +86293ac<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230823180653&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 23 日星期三 22:06:54 +0000</lastbuilddate><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>对疑似冠状动脉疾病的稳定门诊患者进行延迟检测：精确随机临床试验的预先指定二次分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610768/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823180653&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在患有疑似 CAD 的有症状参与者中，通过 PMRS 确定的最小风险指导了最初推迟测试的策略。该策略是安全的，没有观察到不良结果事件，无阻塞性 CAD 的插管次数较少，与平常相比，症状缓解类似测试。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 23 日。doi：10.1001/jamacardio.2023.2614。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：指南建议推迟对疑似冠状动脉疾病 (CAD) 且预检概率较低的有症状人群进行检测。据我们所知，尚无随机试验对这一策略进行前瞻性评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估推迟检测时被确定为 CAD 风险最低的人群的护理过程和健康结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：这项随机、务实的有效性试验包括在 65 个北美和欧洲地点进行的 PRECISE 试验的预先指定的亚组分析。通过经过验证的 PROMISE 最低风险评分 (PMRS) 确定为最低风险的参与者也包括在内。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预：使用 PMRS 进行精确策略的随机化，将那些风险最小的人分配到延迟测试，将其他人分配到冠状动脉计算机断层扫描血管造影，并使用选择性计算机断层扫描衍生的血流储备分数，或进行常规测试（压力测试或屏蔽 PMRS 的导管插入术）。按 PMRS 风险进行随机分层。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果：全因死亡、非致命性心肌梗塞 (MI) 或 12 个月内无阻塞性 CAD 插管的综合结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 2103 名参与者中，422 名被确定为最低风险 (20%)，并随机接受延迟测试 (n = 214) 或常规测试 (n = 208)。平均年龄 (SD) 为 46 (8.6) 岁；304 名女性(72%)。在随访期间，随机分配到延迟测试的人中有 138 人从未进行过测试 (64%)，而 76 人进行了下游测试 (36%)（中位 [IQR] 48 [15-78] 天）恶化 (30%)、不受控制 (10%) 或新症状 (6%)，或改变临床医生偏好 (19%) 或参与者偏好 (10%)。这些测试中 96% 的结果正常。发生在 2 次推迟测试参与者 (0.9%) 和 13 名常规测试参与者 (6.3%)（风险比，0.15；95% CI，0.03-0.66；P = .01）。延迟测试参与者中没有观察到死亡或心肌梗死，而 1 名非心血管死亡1 例 MI 发生在常规测试组。延迟测试组有 2 名参与者 (0.9%) 进行了无阻塞性 CAD 的导管插入术，12 名参与者 (5.8%) 进行了常规测试 (P = .02)。在基线时，70% 的参与者有12 个月时，两组的频繁心绞痛减少率均低于 20%。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在患有疑似 CAD 的有症状参与者中，通过 PMRS 确定的最小风险指导了最初推迟测试的策略。该策略是安全的，没有观察到不良结果事件，无阻塞性 CAD 的插管次数较少，与平常相比，症状缓解类似测试。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT03702244。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610768/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37610768</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2614>10.1001/jamacardio.2023.2614</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610768</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——詹姆斯·E·乌德尔森</dc:creator><dc:creator>米歇尔·D·凯尔西</dc:creator><dc:creator>迈克尔·G·南纳</dc:creator><dc:creator>——克里斯托弗·B·福代斯</dc:creator><dc:creator>尤里克</dc:creator><dc:creator>——罗伯特·M·克莱尔</dc:creator><dc:creator>丹尼尔·B·马克</dc:creator><dc:creator>马内什·R·帕特尔</dc:creator><dc:creator>坎贝尔·罗杰斯</dc:creator><dc:creator>尼克·科森</dc:creator><dc:creator>詹卢卡·庞托内</dc:creator><dc:creator>帕尔·毛罗维奇-霍瓦特</dc:creator><dc:creator>伯纳德·德布劳内</dc:creator><dc:creator>——约翰·P·格林伍德</dc:creator><dc:creator>维克托·马里内斯库</dc:creator><dc:creator>乔纳森·莱普西克</dc:creator><dc:creator>格雷格·W·斯通</dc:creator><dc:creator>奥里·本-耶胡达</dc:creator><dc:creator>科林·贝瑞</dc:creator><dc:creator>谢伊·霍根</dc:creator><dc:creator>比约恩·雷德福斯</dc:creator><dc:creator>齐亚德·阿​​里</dc:creator><dc:creator>——罗伯特·A·伯恩</dc:creator><dc:creator>——克里斯托弗·M·克莱默</dc:creator><dc:creator>——罗伯特·W·叶</dc:creator><dc:creator>贝丝·马丁内斯更多</dc:creator><dc:creator>莎拉·马伦</dc:creator><dc:creator>惠特尼·休伊</dc:creator><dc:creator>——凯文·J·安斯特罗姆</dc:creator><dc:creator>侯赛因·卡里迪</dc:creator><dc:creator>凯伦·奇斯韦尔</dc:creator><dc:creator>斯里坎特·韦穆拉帕利</dc:creator><dc:creator>帕梅拉·道格拉斯</dc:creator><dc:creator>精确调查员</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>对疑似冠状动脉疾病的稳定门诊患者进行延迟检测：精确随机临床试验的预先指定二次分析</dc:title><dc:identifier>下午：37610768</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2614</dc:identifier></item><item><title>微血管心绞痛患者的冠状静脉压和微血管血流动力学：一项随机临床试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610757/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823180653&amp;v=2.17.9.post6+86293ac<description>结论和相关性：冠状静脉压升高导致微血管心绞痛患者微血管阻力降低，这种机制对这种复杂疾病的治疗具有潜在影响。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 23 日。doi：10.1001/jamacardio.2023.2566。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：冠状静脉循环在调节心肌灌注中的作用及其治疗微血管心绞痛的潜力尚未被探索。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估冠状静脉压的增加是否会改变微血管心绞痛患者的微血管阻力。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：这是一项盲法、假对照、交叉随机临床试验，在 2021 年 11 月至 2023 年 1 月期间招募了参与者。这项生理学终点研究的参与者是从德国美因茨。因微血管功能障碍（根据基于热稀释的微血管阻力指数 >;25 mm Hg × s 定义）而患有中度/重度心绞痛（加拿大心血管学会 2-4 级）的患者。排除标准为心外膜冠状动脉疾病.、二度和三度房室传导阻滞、严重瓣膜性心脏病、心肌病、肺病或肾病。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预：将放置在心脏冠状窦（CS）中的尺寸较小的气球（以下简称气球）充气，将放气的气球放置在右心房中，称为假手术。在休息时和最大冠状动脉充血期间进行测量。最后评估者对随机序列不知情。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和测量：血流动力学参数，包括主动脉 (Pa) 和远端 (Pd) 冠状动脉压力、冠状窦压力 (Pcs)、右心房压力 (Pra) 和平均通过时间（血流倒数 [Tmn]），被测量。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：本研究共纳入 20 名患者（中位 [IQR] 年龄，69 [64-75] 岁；11 名女性 [55.0%]）。其中 2 名患者 (10%) 患有糖尿病，6 名患者 (30%) 患有糖尿病。高胆固醇血症，15 名（75%）患有高血压，3 名（15%）是经常吸烟者。CS 球囊的充气导致静息时和充血期间的 CS 压力显着增加（与对照组相比，分别增加了 300% 和 317%）假手术，均 P &lt; .001），充血远端冠状动脉压力降低（中位 [IQR]，假手术：98 [88-110] mm Hg；球囊：89 [84-102] mm Hg；P = .01）和中位 (IQR) 通过时间（假手术：0.39 [0.23-0.62] s；球囊：0.26 [0.17-0.46] s；P &lt; .001）。因此，CS 闭塞导致静息冠状动脉阻力（中位）下降[IQR]，假手术：59 [37-87] mm Hg × s；球囊：42 [31-67] mm Hg × s；P = .005）和主要终点充血性冠状动脉阻力（平均 [IQR]，假手术）球囊：14 [8-26] mm Hg × s；P &lt; .001)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：冠状静脉压升高导致微血管心绞痛患者微血管阻力降低，这种机制对这种复杂疾病的治疗具有潜在影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT05034224。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610757/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37610757</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2566>10.1001/jamacardio.2023.2566</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610757</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>海伦·乌尔里希</dc:creator><dc:creator>菲利普·哈默</dc:creator><dc:creator>马克西米利安·奥尔舍夫斯基</dc:creator><dc:creator>托马斯·明泽尔</dc:creator><dc:creator>哈维尔扫描</dc:creator><dc:creator>托马索·戈里</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>微血管心绞痛患者的冠状静脉压和微血管血流动力学：一项随机临床试验</dc:title><dc:identifier>下午：37610757</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2566</dc:identifier></item><item><title>低风险胸痛延迟检测的建议——已有数十年历史，但现在终于得到了检测</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610740/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823180653&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 23 日。doi：10.1001/jamacardio.2023.2715。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610740/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37610740</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2715>10.1001/jamacardio.2023.2715</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610740</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>雷蒙德·J·吉本斯</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>低风险胸痛延迟检测的建议——已有数十年历史，但现在终于得到了检测</dc:title><dc:identifier>下午：37610740</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2715</dc:identifier></item><item><title>美国鱼油补充剂的健康声明和剂量</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610733/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823180653&amp;v=2.17.9.post6+86293ac<description>结论：这项横断面研究的结果表明，大多数鱼油补充剂标签都做出了健康声明，通常以结构/功能声明的形式，暗示对各种器官系统的健康益处，尽管缺乏试验数据表明功效。现有补充剂中 EPA+DHA 的每日剂量存在显着的异质性，导致补充剂之间的安全性和功效存在潜在差异。对膳食补充剂的监管加强…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 23 日。doi：10.1001/jamacardio.2023.2424。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：尽管多项随机临床试验显示，没有关于补充剂范围剂量对心血管有益的数据，但在 60 岁以上的美国成年人中，有五分之一经常服用鱼油补充剂来维持心脏健康。补充剂标签上的声明可能会影响消费者对健康益处的看法。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估美国鱼油补充剂标签上的健康声明，并检查常用配方中二十碳五烯酸 (EPA) 和二十二碳六烯酸 (DHA) 的剂量。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、设置和参与者：这项横断面研究使用了来自美国国立卫生研究院膳食补充剂标签数据库的市售鱼油（和非鱼 ω-3 脂肪酸）补充剂标签数据。分析时间为 2022 年 2 月至 6 月。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和措施：对鱼油标签上健康声明的频率和类型（美国食品和药物管理局 [FDA] 审查的合格健康声明与结构/功能声明）以及所引用的器官系统进行了评估。对来自 16 家领先制造商和零售商的 DHA (EPA+DHA) 补充剂进行了评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 2819 种独特的鱼油补充剂中，2082 种 (73.9%) 至少提出了 1 项健康声明。其中，只有 399 种 (19.2%) 使用了 FDA 批准的合格健康声明；其余的 (1683 种 [80.8%]) 仅做出了结构/功能声明（例如，“促进心脏健康”）。心血管健康声明是最常见的（1747 [62.0%]）。在 16 个领先品牌/制造商中，确定了 255 种鱼油补充剂。每日 EPA 剂量（中位数 [IQR]，340 [135-647] mg/d)、DHA（中位数 [IQR]，270 [140-500] mg/d）和总 EPA+DHA（中位数 [IQR]，600 [300-1100] ] mg/d)。在评估的 255 种补充剂中，只有 24 种 (9.4%) 含有每日剂量 2 克或更多的 EPA+DHA。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项横断面研究的结果表明，大多数鱼油补充剂标签都做出了健康声明，通常以结构/功能声明的形式，暗示对各种器官系统的健康益处，尽管缺乏试验数据表明功效。现有补充剂中 EPA+DHA 的每日剂量存在显着的异质性，导致补充剂之间的安全性和功效存在潜在差异。可能需要加强膳食补充剂标签的监管，以防止消费者错误信息。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610733/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37610733</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2424>10.1001/jamacardio.2023.2424</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610733</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>乔安娜·N·阿萨杜里安</dc:creator><dc:creator>——埃里克·D·彼得森</dc:creator><dc:creator>塞缪尔·麦克唐纳</dc:creator><dc:creator>阿南德·古普塔更多</dc:creator><dc:creator>——安-玛丽·纳瓦尔</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>美国鱼油补充剂的健康声明和剂量</dc:title><dc:identifier>下午：37610733</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2424</dc:identifier></item><item><title>为疑似冠状动脉疾病制定精确诊断策略——从 PRECISE 试验中汲取的经验教训</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610732/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823180653&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 23 日。doi：10.1001/jamacardio.2023.2696。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610732/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37610732</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2696>10.1001/jamacardio.2023.2696</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610732</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>克里希纳·K·帕特尔</dc:creator><dc:creator>莱斯利·J·肖</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>为疑似冠状动脉疾病制定精确诊断策略——从 PRECISE 试验中汲取的经验教训</dc:title><dc:identifier>下午：37610732</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2696</dc:identifier></item><item><title>对疑似冠状动脉疾病的症状稳定的患者进行基于风险的初始检测策略与常规检测的比较：精确随机临床试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610731/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823180653&amp;v=2.17.9.post6+86293ac<description>结论和相关性：稳定胸痛的初步诊断方法从定量风险分层开始，对最低风险患者进行延迟测试，并在所有其他患者中进行选择性 FFR-CT 的 cCTA 相对于 UT 提高 1 年的临床效率。需要验证这些发现，包括安全。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 23 日。doi：10.1001/jamacardio.2023.2595。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：对稳定胸痛患者进行的初步评估显示，与压力测试相比，使用冠状动脉计算机断层扫描血管造影 (cCTA) 进行的初步评估具有相同或更好的结果，这些试验为指南提供了参考，但提出了关于过度测试和过度插管的问题。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：测试修改后的初始 cCTA 策略，该策略旨在与常规测试 (UT) 相比提高临床效率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：这是一项务实的随机临床试验，招募了2018年12月3日至2021年5月18日的参与者，中位随访时间为11.8个月。来自北美和欧洲65个地点且症状稳定的患者疑似冠状动脉疾病 (CAD) 且既往未进行过检测的患者以 1:1 的比例随机分配至精准策略 (PS) 或 UT。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预措施：PS 纳入了评估胸痛的前瞻性多中心影像研究 (PROMISE) 最低风险评分，以定量选择最低风险参与者进行延期测试，将所有其他参与者分配给具有选择性 CT 衍生血流储备分数 (FFR-CT) 的 cCTA UT 包括选定地点的压力测试或导管插入术。现场临床医生决定后续护理。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结局和指标：结局是将临床效率（无阻塞性 CAD 的侵入性导管插入术）和安全性（死亡或非致命性心肌梗塞 [MI]）合并为复合主要终点。次要终点包括主要结局的安全性组成部分和药物使用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共有 2103 名参与者（平均 [SD] 年龄，58.4 [11.5] 岁；1056 名男性 [50.2%]）被纳入研究，1057 名参与者中有 44 名参与者中有 422 名 [20.1%] 被归类为最低风险。 PS 组中有 118 名参与者 (4.2%)，UT 组有 1046 名参与者中的 118 名参与者 (11.3%)（风险比 [HR]，0.35；95% CI，0.25-0.50）。PS，无阻塞性疾病的导管插入率较低(27 [2.6%]) 与 UT 参与者 (107 [10.2%]；HR，0.24；95% CI，0.16-0.36)。HR，1.52；95% CI，0.73-3.15)。5 人死亡 (0.5 PS 组有 7 例 (0.7%) 发生，而 UT 组有 7 例 (0.7%) (HR, 0.71; 95% CI, 0.23-2.23)，PS 组有 13 例 (1.2%) 发生非致命性心梗，而 UT 组有 5 例 (0.5%) ）在 UT 组（HR，2.65；95% CI，0.96–7.36）。%] 对比 873 例中的 365 例 [41.8%]）和抗血小板药物（900 例中的​​ 321 例 [35.7%] 对比 873 例中的 237 例 [27.1%]） 1 年时，PS 组的死亡率高于 UT 组（均 P &lt; . 001）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：稳定胸痛的初步诊断方法从定量风险分层开始，对最低风险患者进行延迟测试，并在所有其他患者中进行选择性 FFR-CT 的 cCTA 相对于 UT 提高 1 年的临床效率。需要验证这些发现，包括安全。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT03702244。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610731/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37610731</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2595>10.1001/jamacardio.2023.2595</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610731</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>帕梅拉·道格拉斯</dc:creator><dc:creator>迈克尔·G·南纳</dc:creator><dc:creator>米歇尔·D·凯尔西</dc:creator><dc:creator>尤里克</dc:creator><dc:creator>丹尼尔·B·马克</dc:creator><dc:creator>马内什·R·帕特尔</dc:creator><dc:creator>坎贝尔·罗杰斯</dc:creator><dc:creator>——詹姆斯·E·乌德尔森</dc:creator><dc:creator>——克里斯托弗·B·福代斯</dc:creator><dc:creator>尼克·科森</dc:creator><dc:creator>詹卢卡·庞托内</dc:creator><dc:creator>帕尔·毛罗维奇-霍瓦特</dc:creator><dc:creator>伯纳德·德布劳内</dc:creator><dc:creator>——约翰·P·格林伍德</dc:creator><dc:creator>维克托·马里内斯库</dc:creator><dc:creator>乔纳森·莱普西克</dc:creator><dc:creator>格雷格·W·斯通</dc:creator><dc:creator>奥里·本-耶胡达</dc:creator><dc:creator>科林·贝瑞</dc:creator><dc:creator>谢伊·霍根</dc:creator><dc:creator>比约恩·雷德福斯</dc:creator><dc:creator>齐亚德·阿​​里</dc:creator><dc:creator>——罗伯特·A·伯恩</dc:creator><dc:creator>——克里斯托弗·M·克莱默</dc:creator><dc:creator>——罗伯特·W·叶</dc:creator><dc:creator>贝丝·马丁内斯更多</dc:creator><dc:creator>莎拉·马伦</dc:creator><dc:creator>惠特尼·休伊</dc:creator><dc:creator>——凯文·J·安斯特罗姆</dc:creator><dc:creator>侯赛因·卡里迪</dc:creator><dc:creator>斯里坎特·韦穆拉帕利</dc:creator><dc:creator>精确调查员</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>对疑似冠状动脉疾病的症状稳定的患者进行基于风险的初始检测策略与常规检测的比较：精确随机临床试验</dc:title><dc:identifier>下午：37610731</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2595</dc:identifier></item><item><title>心力衰竭治疗全球优化的必要性：一些差异并不重要</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610399/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823180653&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 2 日：S0735-1097(23)05963-6。doi：10.1016/j.jacc.2023.06.007。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610399/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37610399</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.007>10.1016/j.jacc.2023.06.007</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610399</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>贾维德·巴特勒</dc:creator><dc:creator>穆罕默德·沙泽布·汗更多</dc:creator><dc:creator>格雷格·C·福纳罗</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心力衰竭治疗全球优化的必要性：一些差异并不重要</dc:title><dc:identifier>下午：37610399</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.007</dc:identifier></item><item><title>根据心力衰竭患者地理位置的达格列净疗效</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610398/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823180653&amp;v=2.17.9.post6+86293ac<description>结论：尽管患者特征、背景治疗和事件发生率存在地理差异，但达格列净的疗效和安全性在全球各地区是一致的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 2 日：S0735-1097(23)05964-8。doi：10.1016/j.jacc.2023.05.056。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：由于心力衰竭（HF）患者的临床特征和预后因地理区域的不同而不同，因此对治疗的反应也可能有所不同。之前的一份报告表明，钠-葡萄糖协同转运蛋白2抑制剂对射血减少的心力衰竭的疗效分数 (HFrEF) 可以按地区修改。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究的目的是根据地理区域检查达格列净对心力衰竭患者的疗效和安全性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们对 DAPA-HF（达格列净和预防心力衰竭不良后果）和 DELIVER（达格列净改善射血分数保留心力衰竭患者的生活的评估）试验进行了患者层面的汇总分析，评估了效果达格列净分别治疗 HFrEF 和射血分数轻度降低的心力衰竭 (HFmrEF)/射血分数保留的心力衰竭 (HFpEF)。主要结局是心力衰竭恶化或心血管死亡的复合结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 11,007 名患者中，欧洲有 5,159 名患者（46.9%）入组，北美有 1,528 名患者（13.9%）入组，南美洲有 1,998 名患者（18.2%）入组，亚洲有 2,322 名患者（21.1%）入组（每 100 人年）。北美 (13.9 [95% CI: 12.5-15.4]) 高于其他地区：欧洲 10.8 (95% CI: 10.1-11.5)、南美洲 10.0 (95% CI: 9.0-11.1) 和亚洲 10.5 ( 95% CI: 9.5-11.5). 达格列净对主要结局的益处未因地区而改变：达格列净与安慰剂 HR：欧洲，0.85 (95% CI: 0.75-0.96)；北美，0.75 (95% CI: 0.61-0.93）；南美洲，0.72（95% CI：0.58-0.89）；亚洲，0.74（95% CI：0.61-0.91）（P 相互作用 = 0.40）。单独评估 HFrEF 时（P 相互作用 = 0.39）和 HFmrEF/HFpEF（P 交互作用 = 0.84）。北美患者比其他地区的患者更频繁地终止随机治疗（安慰剂终止：北美为 21.8%，南美为 6.4%），但安慰剂和安慰剂之间的终止率没有差异。达格列净按地区划分。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：尽管患者特征、背景治疗和事件发生率存在地理差异，但达格列净的疗效和安全性在全球各地区是一致的。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610398/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37610398</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.056>10.1016/j.jacc.2023.05.056</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610398</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>近藤彻</dc:creator><dc:creator>王晓文</dc:creator><dc:creator>杨明明</dc:creator><dc:creator>帕迪普·S·琼德</dc:creator><dc:creator>——布莱恩·L·克拉吉特</dc:creator><dc:creator>穆蒂亚·瓦杜加纳坦</dc:creator><dc:creator>——阿德里安·F·埃尔南德斯</dc:creator><dc:creator>卡罗琳·SP·林</dc:creator><dc:creator>西尔维奥·因祖奇</dc:creator><dc:creator>费利佩·马丁内斯</dc:creator><dc:creator>鲁道夫·德波尔</dc:creator><dc:creator>米哈伊尔·N·科西博罗德</dc:creator><dc:creator>Akshay S Desai更多</dc:creator><dc:creator>拉斯·科伯</dc:creator><dc:creator>彼得·波尼科夫斯基</dc:creator><dc:creator>马克·S·萨巴廷</dc:creator><dc:creator>安娜·玛丽亚·朗基尔德</dc:creator><dc:creator>马格努斯·彼得森</dc:creator><dc:creator>纳塔利娅·扎泽斯卡</dc:creator><dc:creator>伊拉斯谟·巴克斯</dc:creator><dc:creator>斯科特·D·所罗门</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>根据心力衰竭患者地理位置的达格列净疗效</dc:title><dc:identifier>下午：37610398</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.056</dc:identifier></item><item><title>异常的淋巴鞘氨醇-1-磷酸信号传导会加剧淋巴功能障碍和组织炎症</title><link/>https://pubmed.ncbi.nlm.nih.gov/37609838/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823180653&amp;v=2.17.9.post6+86293ac<description>结论：这项研究表明，LEC S1P 信号传导的减少通过增强 LEC 粘附和放大致病性 CD4 T 细胞反应而加重淋巴水肿。P-选择素抑制剂被建议作为这种普遍病症的可能治疗方法。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 23 日。doi：10.1161/CIRCULATIONAHA.123.064181。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：淋巴水肿是一个全球性的健康问题，目前尚无有效的药物治疗方法。增强的 T 细胞免疫力和异常的淋巴内皮细胞 (LEC) 信号传导是该疾病有希望的治疗靶点。1-磷酸鞘氨醇 (S1P) 介导所需的关键信号通路对于正常的 LEC 功能，LEC 中 S1P 信号传导的改变可能导致淋巴疾病和致病性 T 细胞激活。表征这种生物学特征对于开发急需的疗法相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：研究人和小鼠淋巴水肿。通过手术结扎尾部淋巴管在小鼠中诱导淋巴水肿。评估淋巴水肿真皮组织的 S1P 信号传导。为了验证改变的 S1P 信号传导效应在淋巴细胞中的作用，LEC 特异性<i>S1pr1</i>缺陷（随着时间的推移，通过尾部体积和组织病理学测量来量化疾病进展。来自小鼠和<sup>人类</sup>的<i>LEC</i> ，具有 S1P 信号传导抑制，然后与 CD4 T 细胞共培养，然后分析 CD4 T 细胞激活和通路信号传导。用 P-选择素特异性单克隆抗体治疗动物，以评估其减少淋巴水肿和 T 细胞活化的功效。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：人类和实验性淋巴水肿组织通过 S1P 受体 1 (S1PR1) 证明了 LEC S1P 信号传导。LEC <i>S1pr1</i>功能丧失加剧了小鼠淋巴水肿中的淋巴血管功能不全、尾部肿胀减少以及 CD4 T 细胞浸润增加。 <i>S1pr1</i> <sup>LECKO</sup>小鼠与 CD4 T 细胞共培养，导致淋巴细胞分化增强。抑制人真皮 LEC 中的 S1PR1 信号传导，通过与淋巴细胞直接接触促进 T 辅助细胞 1 型和 2 型（Th1 和 Th2）细胞分化。人真皮 LEC 受到抑制S1P 信号传导显示增强的 P-选择素（一种在活化血管细胞上表达的重要细胞粘附分子）。在体外，P-选择素阻断可减少与<i>shS1PR1</i>处理的人真皮 LEC 共培养的 Th 细胞的活化和分化。改善尾部并减少 Th1/ 肿胀小鼠淋巴水肿中的 Th2 免疫反应。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究表明，LEC S1P 信号传导的减少通过增强 LEC 粘附和放大致病性 CD4 T 细胞反应而加重淋巴水肿。P-选择素抑制剂被建议作为这种普遍病症的可能治疗方法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37609838/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37609838</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064181>10.1161/CIRCULATIONAHA.123.064181</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37609838</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>金东健</dc:creator><dc:creator>文田</dc:creator><dc:creator>吴廷轩</dc:creator><dc:creator>梦兰乡</dc:creator><dc:creator>瑞安·文恩</dc:creator><dc:creator>——贾森·朗·张</dc:creator><dc:creator>谷申彪</dc:creator><dc:creator>李升熙</dc:creator><dc:creator>于朱</dc:creator><dc:creator>Torreyguan更多</dc:creator><dc:creator>埃米莉·克莱尔·施奈德</dc:creator><dc:creator>Evan Bao更多</dc:creator><dc:creator>J·布兰登·迪克森</dc:creator><dc:creator>Peter Kao更多</dc:creator><dc:creator>潘俊良</dc:creator><dc:creator>——斯坦利·洛克森</dc:creator><dc:creator>蒋新国</dc:creator><dc:creator>——马克·罗伯特·尼科尔斯</dc:creator><dc:date>2023-08-23</dc:date><dc:source>循环</dc:source><dc:title>异常的淋巴鞘氨醇-1-磷酸信号传导会加剧淋巴功能障碍和组织炎症</dc:title><dc:identifier>下午：37609838</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064181</dc:identifier></item><item><title>房性和室性心律失常的长期风险：“癫痫性心脏”的主要表现</title><link/>https://pubmed.ncbi.nlm.nih.gov/37608403/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823180653&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 22 日：ehad524。doi：10.1093/eurheartj/ehad524。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37608403/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37608403</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad524>10.1093/eurheartj/ehad524</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37608403</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——理查德·L·维里尔</dc:creator><dc:creator>彭楚迪</dc:creator><dc:creator>史蒂文·C·沙赫特</dc:creator><dc:date>2023-08-23</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>房性和室性心律失常的长期风险：“癫痫性心脏”的主要表现</dc:title><dc:identifier>下午：37608403</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad524</dc:identifier></item><item><title>线虫跨多个时间尺度和状态的全脑行为表征</title><link/>https://pubmed.ncbi.nlm.nih.gov/37607537/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823180653&amp;v=2.17.9.post6+86293ac<description>动物行为和内部状态的变化伴随着自由移动的秀丽隐杆线虫大脑活动的广泛变化，并建立了概率模型来解释每个神经元如何编码定量行为特征。通过确定记录的神经元的身份，我们创建了一本关于……的地图集</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 14 日：S0092-8674(23)00850-4.doi: 10.1016/j.cell.2023.07.035. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">动物行为和内部状态的变化伴随着自由移动的秀丽隐杆线虫大脑活动的广泛变化，并建立了概率模型来解释每个神经元如何编码定量行为特征。通过确定记录的神经元的身份，我们创建了线虫连接组中定义的神经元类别如何编码行为的图谱。此外，尽管许多神经元编码当前的运动动作，但其他神经元则整合最近的动作。行为状态的变化伴随着神经元编码行为方式的广泛变化，我们确定连接组中的这些灵活节点提供了动物大脑中的细胞类型如何编码其行为的全局图。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37607537/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37607537</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.035>10.1016/j.cell.2023.07.035</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37607537</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator>亚当·阿塔纳斯</dc:creator><dc:creator>金正洙</dc:creator><dc:creator>王子玉</dc:creator><dc:creator>埃里克·布埃诺 (Eric Bueno)</dc:creator><dc:creator>麦考伊·贝克尔</dc:creator><dc:creator>迪康</dc:creator><dc:creator>朴正渊</dc:creator><dc:creator>塔利亚·克莱默</dc:creator><dc:creator>温芙蓉</dc:creator><dc:creator>萨巴巴斯科伊鲁</dc:creator><dc:creator>Ugur Dag更多</dc:creator><dc:creator>埃尔皮尼基·卡洛格罗普鲁</dc:creator><dc:creator>——马修·A·戈麦斯</dc:creator><dc:creator>卡西·埃斯特雷姆</dc:creator><dc:creator>内塔·科恩</dc:creator><dc:creator>Vikash K Mansinghka更多</dc:creator><dc:creator>——史蒂文·W·弗拉维尔</dc:creator><dc:date>2023-08-22</dc:date><dc:source>细胞</dc:source><dc:title>线虫跨多个时间尺度和状态的全脑行为表征</dc:title><dc:identifier>下午：37607537</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.035</dc:identifier></item><item><title>人类自然杀伤细胞的泛癌单细胞全景图</title><link/>https://pubmed.ncbi.nlm.nih.gov/37607536/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823180653&amp;v=2.17.9.post6+86293ac<description>自然杀伤 (NK) 细胞在对抗肿瘤进展的先天免疫反应中发挥着不可或缺的作用。为了描述其在肿瘤微环境中的表型和功能多样性，我们对来自 716 名癌症患者的 NK 细胞进行了综合单细胞 RNA 测序分析，涵盖了 24 种癌症类型。我们以肿瘤类型特异性的方式观察到 NK 细胞组成的异质性。值得注意的是，我们已经鉴定出一组在肿瘤中富集的肿瘤相关 NK 细胞，显示... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 15 日：S0092-8674(23)00849-8.doi: 10.1016/j.cell.2023.07.034.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Natural killer (NK) cells play indispensable roles in innate immune responses against tumor progression. To depict their phenotypic and functional diversities in the tumor microenvironment, we perform integrative single-cell RNA sequencing analyses on NK cells from 716 patients with cancer, covering 24 cancer types. We observed heterogeneity in NK cell composition in a tumor-type-specific manner. Notably, we have identified a group of tumor-associated NK cells that are enriched in tumors, show impaired anti-tumor functions, and are associated with unfavorable prognosis and resistance to immunotherapy. Specific myeloid cell subpopulations, in particular LAMP3 <sup>+</sup> dendritic cells, appear to mediate the regulation of NK cell anti-tumor immunity. Our study provides insights into NK-cell-based cancer immunity and highlights potential clinical utilities of NK cell subsets as therapeutic targets.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37607536/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37607536</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.034>10.1016/j.cell.2023.07.034</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37607536</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Fei Tang</dc:creator><dc:creator> Jinhu Li</dc:creator><dc:creator> Lu Qi</dc:creator><dc:creator> Dongfang Liu</dc:creator><dc:creator> Yufei Bo</dc:creator><dc:creator> Shishang Qin</dc:creator><dc:creator> Yuhui Miao</dc:creator><dc:creator> Kezhuo Yu</dc:creator><dc:creator> Wenhong Hou</dc:creator><dc:creator> Jianan Li</dc:creator><dc:creator> Jirun Peng</dc:creator><dc:creator> Zhigang Tian</dc:creator><dc:creator> Linnan Zhu</dc:creator><dc:creator> Hui Peng</dc:creator><dc:creator> Dongfang Wang</dc:creator><dc:creator> Zemin Zhang</dc:creator><dc:date> 2023-08-22</dc:date><dc:source> Cell</dc:source><dc:title> A pan-cancer single-cell panorama of human natural killer cells</dc:title><dc:identifier> pmid:37607536</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.034</dc:identifier></item><item><title> Antithrombotic treatment: personalized antiplatelet therapies and lessons from the gut microbiota</title><link/> https://pubmed.ncbi.nlm.nih.gov/37607038/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823180653&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 22;44(32):3023-3026. doi: 10.1093/eurheartj/ehad521.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37607038/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37607038</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad521>10.1093/eurheartj/ehad521</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37607038</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Filippo Crea</dc:creator><dc:date> 2023-08-22</dc:date><dc:source> European heart journal</dc:source><dc:title> Antithrombotic treatment: personalized antiplatelet therapies and lessons from the gut microbiota</dc:title><dc:identifier> pmid:37607038</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad521</dc:identifier></item><item><title> Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management</title><link/> https://pubmed.ncbi.nlm.nih.gov/37606064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823180653&amp;v=2.17.9.post6+86293ac<description> Patient-reported outcomes (PROs) provide important insights into patients&#39; own perspectives about their health and medical condition, and there is evidence that their use can lead to improvements in the quality of care and to better-informed clinical decisions. Their application in cardiovascular populations has grown over the past decades. This statement describes what PROs are, and it provides an inventory of disease-specific and domain-specific PROs that have been developed for cardiovascular... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 22:ehad514. doi: 10.1093/eurheartj/ehad514. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Patient-reported outcomes (PROs) provide important insights into patients&#39; own perspectives about their health and medical condition, and there is evidence that their use can lead to improvements in the quality of care and to better-informed clinical decisions. Their application in cardiovascular populations has grown over the past decades. This statement describes what PROs are, and it provides an inventory of disease-specific and domain-specific PROs that have been developed for cardiovascular populations. International standards and quality indices have been published, which can guide the selection of PROs for clinical practice and in clinical trials and research; patients as well as experts in psychometrics should be involved in choosing which are most appropriate. Collaborations are needed to define criteria for using PROs to guide regulatory decisions, and the utility of PROs for comparing and monitoring the quality of care and for allocating resources should be evaluated. New sources for recording PROs include wearable digital health devices, medical registries, and electronic health record. Advice is given for the optimal use of PROs in shared clinical decision-making in cardiovascular medicine, and concerning future directions for their wider application.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37606064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37606064</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad514>10.1093/eurheartj/ehad514</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37606064</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Philip Moons</dc:creator><dc:creator> Tone M Norekvål</dc:creator><dc:creator> Elena Arbelo</dc:creator><dc:creator> Britt Borregaard</dc:creator><dc:creator> Barbara Casadei</dc:creator><dc:creator> Bernard Cosyns</dc:creator><dc:creator> Martin R Cowie</dc:creator><dc:creator> Donna Fitzsimons</dc:creator><dc:creator> Alan G Fraser</dc:creator><dc:creator> Tiny Jaarsma</dc:creator><dc:creator> Paulus Kirchhof</dc:creator><dc:creator> Josepa Mauri</dc:creator><dc:creator> Richard Mindham</dc:creator><dc:creator> Julie Sanders</dc:creator><dc:creator> Francois Schiele</dc:creator><dc:creator> Aleksandra Torbica</dc:creator><dc:creator> Ann Dorthe Zwisler</dc:creator><dc:date> 2023-08-22</dc:date><dc:source> European heart journal</dc:source><dc:title> Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management</dc:title><dc:identifier> pmid:37606064</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad514</dc:identifier></item><item><title> Brain α2δ-1-Bound NMDA Receptors Drive Calcineurin Inhibitor-Induced Hypertension</title><link/> https://pubmed.ncbi.nlm.nih.gov/37605933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823180653&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: These findings indicate that α2δ-1 is essential for calcineurin inhibitor-induced increases in synaptic NMDAR activity in PVN presympathetic neurons and sympathetic outflow. Thus, α2δ-1 and α2δ-1-bound NMDARs represent new targets for treating calcineurin inhibitor-induced hypertension. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Aug 22. doi: 10.1161/CIRCRESAHA.123.322562. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Calcineurin is highly enriched in immune T cells and in the nervous system. Calcineurin inhibitors, including cyclosporine and tacrolimus (FK506), are the cornerstone of immunosuppressive regimens for preserving transplanted organs and tissues. However, these drugs often cause persistent hypertension owing to excess sympathetic outflow, which is maintained by N-methyl-D-aspartate receptor (NMDAR)-mediated excitatory input to the hypothalamic paraventricular nucleus (PVN). It is unclear how calcineurin inhibitors increase NMDAR activity in the PVN to augment sympathetic vasomotor activity. α2δ-1 (encoded by the <i>Cacna2d1</i> gene), known colloquially as a calcium channel subunit, is a newly discovered NMDAR-interacting protein. Here, we determined whether α2δ-1 plays a role in calcineurin inhibitor-induced synaptic NMDAR hyperactivity in the PVN and hypertension development. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS AND RESULTS: Immunoblotting and coimmunoprecipitation assays revealed that prolonged treatment with FK506 in rats significantly increased protein levels of α2δ-1, GluN1 (the obligatory NMDAR subunit), and the α2δ-1-GluN1 complex in PVN synaptosomes. These effects were blocked by inhibiting α2δ-1 with gabapentin or interrupting the α2δ-1-NMDAR interaction with an α2δ-1 C-terminus peptide. Whole-cell recordings in brain slices showed that treatment with FK506 potentiated the activity of presynaptic and postsynaptic NMDARs in spinally projecting PVN neurons; such effects were abolished by gabapentin, <i>Cacna2d1</i> knockout, or α2δ-1 C-terminus peptide. Furthermore, microinjection of α2δ-1 C-terminus peptide into the PVN diminished renal sympathetic nerve discharges and arterial blood pressure that had been increased by FK506 treatment. Remarkably, telemetry recording showed that concurrent administration of gabapentin prevented the development of FK506-induced hypertension in rats. Additionally, FK506 treatment induced sustained hypertension in wild-type mice but not in <i>Cacna2d1</i> knockout mice. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: These findings indicate that α2δ-1 is essential for calcineurin inhibitor-induced increases in synaptic NMDAR activity in PVN presympathetic neurons and sympathetic outflow. Thus, α2δ-1 and α2δ-1-bound NMDARs represent new targets for treating calcineurin inhibitor-induced hypertension.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37605933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37605933</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.322562>10.1161/CIRCRESAHA.123.322562</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37605933</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jing-Jing Zhou</dc:creator><dc:creator> Jian-Ying Shao</dc:creator><dc:creator> Shao-Rui Chen</dc:creator><dc:creator> Hui-Lin Pan</dc:creator><dc:date> 2023-08-22</dc:date><dc:source> Circulation research</dc:source><dc:title> Brain α2δ-1-Bound NMDA Receptors Drive Calcineurin Inhibitor-Induced Hypertension</dc:title><dc:identifier> pmid:37605933</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322562</dc:identifier></item><item><title> Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37605637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823180653&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: MRAs did not influence SGLT2i effects on the composite of HHF/CVD, HHF or all-cause mortality; however, findings hinted at a more pronounced relative reduction in CVD in chronic HF patients regardless of EF who were randomized to SGLT2i and receiving an MRA compared to those randomized to SGLT2i and not receiving MRAs. SGLT2i attenuated the risk of MRA-associated treatment-emergent hyperkalaemia. These findings warrant further validation in well-designed randomized controlled... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 22:ehad522. doi: 10.1093/eurheartj/ehad522. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: To investigate the cardiovascular effects of sodium-glucose co-transporter-2 inhibitors (SGLT2i) with concomitant mineralocorticoid receptor antagonist (MRA) use in heart failure (HF) regardless of ejection fraction (EF) and explore the risk of MRA-associated adverse events in individuals randomized to SGLT2i vs. placebo. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: PubMed/MEDLINE, Web of Science, Embase, and clinical trial registries were searched for randomized controlled trials/post-hoc analyses evaluating SGLT2i in HF with or without MRA use (PROSPERO: CRD42023397129). The main outcomes were composite of first hospitalization or urgent visit for HF/cardiovascular death (HHF/CVD), HHF, and CVD. Others were all-cause mortality, composite renal and safety outcomes. Hazard ratios (HR)/risk ratios were extracted. Fixed-effects meta-analyses and subgroup analyses were performed. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Five eligible studies were included, pooling data from 21 947 people with HF (type 2 diabetes mellitus, n = 10 805). Compared to placebo, randomization to SGLT2i showed a similar reduction in HHF/CVD and HHF in people who were or were not using MRAs [HHF/CVD: hazard ratio (HR) 0.75; 95% confidence interval (CI) 0.68-0.81 vs. HR 0.79; 95% CI 0.72-0.86; P-interaction = .43; HHF: HR 0.74; 95% CI 0.67-0.83 vs. HR 0.71; 95% CI 0.63-0.80; P-interaction = .53], with a suggestion of greater relative reduction in CVD in chronic HF people randomized to SGLT2i and using MRAs irrespective of EF (HR 0.81; 95% CI 0.72-0.91 vs. HR 0.98; 95% CI 0.86-1.13; P-interaction = .034). SGLT2i reduced all-cause mortality (P-interaction = .27) and adverse renal endpoints regardless of MRA use (P-interaction = .73) despite a higher risk of volume depletion with concomitant MRAs (P-interaction = .082). SGLT2i attenuated the risk of mild hyperkalaemia (P-interaction &lt; .001) and severe hyperkalaemia (P-interaction = .051) associated with MRA use. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: MRAs did not influence SGLT2i effects on the composite of HHF/CVD, HHF or all-cause mortality; however, findings hinted at a more pronounced relative reduction in CVD in chronic HF patients regardless of EF who were randomized to SGLT2i and receiving an MRA compared to those randomized to SGLT2i and not receiving MRAs. SGLT2i attenuated the risk of MRA-associated treatment-emergent hyperkalaemia. These findings warrant further validation in well-designed randomized controlled trials.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37605637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37605637</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad522>10.1093/eurheartj/ehad522</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37605637</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Mainak Banerjee</dc:creator><dc:creator> Indira Maisnam</dc:creator><dc:creator> Rimesh Pal</dc:creator><dc:creator> Satinath Mukhopadhyay</dc:creator><dc:date> 2023-08-22</dc:date><dc:source> European heart journal</dc:source><dc:title> Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis</dc:title><dc:identifier> pmid:37605637</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad522</dc:identifier></item><item><title> Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title><link/> https://pubmed.ncbi.nlm.nih.gov/37603606/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823180653&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 22;148(8):e8. doi: 10.1161/CIR.0000000000001177. Epub 2023 Aug 21.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37603606/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37603606</a> | DOI: <a href=https://doi.org/10.1161/CIR.0000000000001177>10.1161/CIR.0000000000001177</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37603606</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:date> 2023-08-21</dc:date><dc:source> Circulation</dc:source><dc:title> Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title><dc:identifier> pmid:37603606</dc:identifier><dc:identifier> doi:10.1161/CIR.0000000000001177</dc:identifier></item><item><title> Bicuspid Aortic Valve and Thoracic Aortic Disease: Further Evidence of Clinically Silent but Deadly Risk to Family Members of Affected Individuals</title><link/> https://pubmed.ncbi.nlm.nih.gov/37603605/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823180653&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 22;148(8):648-650. doi: 10.1161/CIRCULATIONAHA.123.065406. Epub 2023 Aug 21.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37603605/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37603605</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065406>10.1161/CIRCULATIONAHA.123.065406</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37603605</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Siddharth K Prakash</dc:creator><dc:creator> Hector I Michelena</dc:creator><dc:creator> Dianna M Milewicz</dc:creator><dc:date> 2023-08-21</dc:date><dc:source> Circulation</dc:source><dc:title> Bicuspid Aortic Valve and Thoracic Aortic Disease: Further Evidence of Clinically Silent but Deadly Risk to Family Members of Affected Individuals</dc:title><dc:identifier> pmid:37603605</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065406</dc:identifier></item><item><title> Selection and Interpretation of Molecular Diagnostics in Heart Transplantation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37603604/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823180653&amp;v=2.17.9.post6+86293ac<description> The number of heart transplants performed annually in the United States and worldwide continues to increase, but there has been little change in graft longevity and patient survival over the past 2 decades. The reference standard for diagnosis of acute cellular and antibody-mediated rejection includes histologic and immunofluorescence evaluation of endomyocardial biopsy samples, despite invasiveness and high interrater variability for grading histologic rejection. Circulating biomarkers and... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 22;148(8):679-694. doi: 10.1161/CIRCULATIONAHA.123.062847. Epub 2023 Aug 21.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The number of heart transplants performed annually in the United States and worldwide continues to increase, but there has been little change in graft longevity and patient survival over the past 2 decades. The reference standard for diagnosis of acute cellular and antibody-mediated rejection includes histologic and immunofluorescence evaluation of endomyocardial biopsy samples, despite invasiveness and high interrater variability for grading histologic rejection. Circulating biomarkers and molecular diagnostics have shown substantial predictive value in rejection monitoring, and emerging data support their use in diagnosing other posttransplant complications. The use of genomic (cell-free DNA), transcriptomic (mRNA and microRNA profiling), and proteomic (protein expression quantitation) methodologies in diagnosis of these posttransplant outcomes has been evaluated with varying levels of evidence. In parallel, growing knowledge about the genetically mediated immune response leading to rejection (immunogenetics) has enhanced understanding of antibody-mediated rejection, associated graft dysfunction, and death. Antibodies to donor human leukocyte antigens and the technology available to evaluate these antibodies continues to evolve. This review aims to provide an overview of biomarker and immunologic tests used to diagnose posttransplant complications. This includes a discussion of pediatric heart transplantation and the disparate rates of rejection and death experienced by Black patients receiving a heart transplant. This review describes diagnostic modalities that are available and used after transplant and the landscape of future investigations needed to enhance patient outcomes after heart transplantation.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37603604/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37603604</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.062847>10.1161/CIRCULATIONAHA.123.062847</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37603604</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jason F Goldberg</dc:creator><dc:creator> Lauren K Truby</dc:creator><dc:creator> Sean Agbor-Enoh</dc:creator><dc:creator> Annette M Jackson</dc:creator><dc:creator> Christopher R deFilippi</dc:creator><dc:creator> Kiran K Khush</dc:creator><dc:creator> Palak Shah</dc:creator><dc:date> 2023-08-21</dc:date><dc:source> Circulation</dc:source><dc:title> Selection and Interpretation of Molecular Diagnostics in Heart Transplantation</dc:title><dc:identifier> pmid:37603604</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.062847</dc:identifier></item><item><title> Ethanol-Induced Atrial Fibrillation Results From Late &lt;em>;I&lt;/em>;&lt;sub>;Na&lt;/sub>; and Can Be Prevented by Ranolazine</title><link/> https://pubmed.ncbi.nlm.nih.gov/37603603/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823180653&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 22;148(8):698-700. doi: 10.1161/CIRCULATIONAHA.123.064561. Epub 2023 Aug 21.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37603603/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37603603</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10437457/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">PMC10437457</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064561>10.1161/CIRCULATIONAHA.123.064561</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37603603</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Julian Mustroph</dc:creator><dc:creator> Maria J Baier</dc:creator><dc:creator> Denise Unsin</dc:creator><dc:creator> Zdenek Provaznik</dc:creator><dc:creator> Kostiantyn Kozakov</dc:creator><dc:creator> Simon Lebek</dc:creator><dc:creator> Daniel Tarnowski</dc:creator><dc:creator> Sönke Schildt</dc:creator><dc:creator> Niels Voigt</dc:creator><dc:creator> Stefan Wagner</dc:creator><dc:creator> Lars S Maier</dc:creator><dc:creator> Stefan Neef</dc:creator><dc:date> 2023-08-21</dc:date><dc:source> Circulation</dc:source><dc:title> Ethanol-Induced Atrial Fibrillation Results From Late &lt;em>;I&lt;/em>;&lt;sub>;Na&lt;/sub>; and Can Be Prevented by Ranolazine</dc:title><dc:identifier> pmid:37603603</dc:identifier><dc:identifier> pmc:PMC10437457</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.064561</dc:identifier></item><item><title> Letter by Teng et al Regarding Article, &quot;Gut Microbiota-Derived Trimethylamine N-Oxide Contributes to Abdominal Aortic Aneurysm Through Inflammatory and Apoptotic Mechanisms&quot;</title><link/> https://pubmed.ncbi.nlm.nih.gov/37603602/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823180653&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 22;148(8):701-702. doi: 10.1161/CIRCULATIONAHA.123.065557. Epub 2023 Aug 21.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37603602/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823180653&v=2.17.9.post6+86293ac">37603602</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065557>10.1161/CIRCULATIONAHA.123.065557</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37603602</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Zhenqing Teng</dc:creator><dc:creator> Xiang Ma</dc:creator><dc:creator> Yitong Ma</dc:creator><dc:date> 2023-08-21</dc:date><dc:source> Circulation</dc:source><dc:title> Letter by Teng et al Regarding Article, &quot;Gut Microbiota-Derived Trimethylamine N-Oxide Contributes to Abdominal Aortic Aneurysm Through Inflammatory and Apoptotic Mechanisms&quot;</dc:title><dc:identifier> pmid:37603602</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065557</dc:identifier></item></channel></rss>